3Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma [ J]. Clin Cancer Res, 2013, 19 ( 13 ) : 3337- 3344.
4Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma [ J ]. Leukemia, 2009, 23( 1 ) :3-9.
5Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European Myeloma Network on interphase FISH in multiplemyeloma and related disorders [ J ]. Haematologica, 2012,97 ( 8 ) : 1272-1277.
6Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics[ J]. Blood, 2012, 119(9) :2100-2105.
7Petrucci MT, Levi A, Bringhen S, et al. Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a muhicenter, open label phase 1/2 study[J]. Cancer, 2013, 119(5) :971-977.
8Rajkumar SV, Blood E, Vesole D, et al. Phase In clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group[ J]. J Clin Oncol, 2006, 24(3) :431-436.
9Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma[ J ]. Haematologica, 2008, 93 ( 1 ) : 124-127.
10Jagannath S, Durie BG, Wolf JL, et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma [J]. Br J Haematol, 2009, 146(6) :619-626.
